Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.48 |
| ▸ | MGLL | Q99685 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TYR | P14679 | 1/20 | 0.47 |
| ▸ | DAO | P14920 | 1/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 6/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | AGXT | P21549 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30036439 | 0.74 | MAOB (0.63) | KDM4ECYP2A6TDP1FLT3LOXL2 | |
| SCHEMBL103158 | 0.74 | MAOB (0.63) | KDM4ECYP2A6TDP1FLT3LOXL2 | |
| SCHEMBL295184 | 0.73 | HPGD (0.60) | KDM4EHSD17B10TYRDAOAKR1B1 | |
| SCHEMBL276909 | 0.70 | CYP2A6 (0.54) | KDM4ECYP2A6TDP1FLT3LOXL2 | |
| SCHEMBL21179480 | 0.70 | MAOB (0.48) | KDM4ECYP2A6TDP1FLT3LOXL2 | |
| SCHEMBL1009796 | 0.70 | MAOB (0.48) | KDM4ECYP2A6TDP1FLT3LOXL2 | |
| SCHEMBL686830 | 0.70 | KDM4E (0.54) | KDM4ECYP2A6TDP1FLT3LOXL2 | |
| SCHEMBL21494529 | 0.70 | KDM4E (0.48) | KDM4ECYP2A6TDP1FLT3LOXL2 | |
| SCHEMBL2057444 | 0.70 | KDM4E (0.48) | KDM4ECYP2A6TDP1FLT3LOXL2 | |
| SCHEMBL12264 | 0.70 | KDM4E (0.48) | KDM4ECYP2A6TDP1FLT3LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 891 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024089225-A1 | PROCESS FOR THE SYNTHESIS OF METHOXY SUBSTITUTED BENZALDEHYDE COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2024-05-02 | — | — | WO | claimed |
| CN-114957140-A | Axial chiral 1,2, 3-triazole compound and preparation method and application thereof | 温州大学 | 2022-08-30 | — | — | CN | claimed |
| US-10428046-B2 | N-substituted sulfonamide compound and method for producing same | UBE INDUSTRIES, LTD. (JP) | 2019-10-01 | — | — | US | claimed |
| EP-3101017-B1 | 4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2019-06-12 | — | — | EP | claimed |
| EP-2758051-B1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-04-11 | — | — | EP | claimed |
| EP-2995617-B1 | BENZOISOTHIAZOLE COMPOUNDS AND USE IN PREPARATION OF ANTIPSYCHOTIC DRUGS | SHANGHAI INST PHARMACEUTICAL IND (CN) | 2018-01-31 | — | — | EP | claimed |
| US-20170114043-A1 | N-SUBSTITUTED SULFONAMIDE COMPOUND AND METHOD FOR PRODUCING SAME | UBE INDUSTRIES, LTD. (JP) | 2017-04-27 | — | — | US | claimed |
| EP-3156396-A1 | N-SUBSTITUTED SULFONAMIDE COMPOUND AND METHOD FOR PRODUCING SAME | UBE Industries, Ltd. (JP) | 2017-04-19 | — | — | EP | claimed |
| EP-2168952-B1 | MORPHOLINE DERIVATIVES AS RENIN INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2017-02-15 | — | — | EP | claimed |
| US-9550741-B2 | Benzoisothiazole compounds and methods of treating schizophrenia | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2017-01-24 | — | — | US | claimed |
| US-4342869-A | Cephalosporin antibiotics | MERCK & CO., INC. (US) | 1982-08-03 | — | — | US | claimed |
| US-4338437-A | Cephalosporin antibiotics | MERCK & CO., INC. (US) | 1982-07-06 | — | — | US | claimed |
| US-4338438-A | Cephalosporin antibiotics | MERCK & CO., INC. (US) | 1982-07-06 | — | — | US | claimed |
| US-4310459-A | Process for producing carbamoyl substituted penams and carbamoyl substituted cephams from penicillin sulfoxide esters | BRISTOL-MYERS COMPANY (US) | 1982-01-12 | — | — | US | claimed |
| US-4298741-A | DETHIAPENICILLIN ANTIBIOTICS | MERCK & CO., INC. (US) | 1981-11-03 | — | — | US | claimed |
| US-4297488-A | 7-α-Methoxy cephalosporins | MERCK & CO., INC. (US) | 1981-10-27 | — | — | US | claimed |
| US-4265819-A | Preparation of dihalogenovinylcyclopropanecarboxylic acids and esters | BAYER AKTIENGESELLSCHAFT (DE) | 1981-05-05 | — | — | US | claimed |
| US-4258040-A | Cephalosporin compounds | MERCK & CO., INC. (US) | 1981-03-24 | — | — | US | claimed |
| US-4217300-A | Preparation of dihalogenovinylcyclopropanecarboxylic acids and esters | BAYER AKTIENGESELLSCHAFT (DE) | 1980-08-12 | — | — | US | claimed |
| US-4060687-A | Cephalosporins having a 3-α substituted alkyl grouping | MERCK & CO., INC. (US) | 1977-11-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114043-A1 | N-SUBSTITUTED SULFONAMIDE COMPOUND AND METHOD FOR PRODUCING SAME | STS, CA7, CA4 | KDM4E 1916/4885CYP2A6 492/4885TDP1 4678/4885 |
| US-10428046-B2 | N-substituted sulfonamide compound and method for producing same | STS, CA7, CA4 | KDM4E 1916/4885CYP2A6 492/4885TDP1 4678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.